News Archives - QualityStocks

ThursdayApr 23, 2026 9:45 am

The Undrilled Basin Thesis: How Greenland Energy Company (NASDAQ: GLND) Is Advancing a 2 million-Acre Arctic Opportunity

Greenland Energy holds rights to up to 70% working interest across three onshore licenses covering more than 2 million acres in East Greenland's Jameson Land Basin. Independent Sproule ERCE engineering estimates indicate recoverable oil upside of 13 billion barrels across the basin, which was extensively evaluated by ARCO decades ago but never drilled. The company has contracted Stampede Drilling for Arctic-rated rig services alongside agreements with Halliburton, Desgagnés, and IPT Well Solutions to support its 2026 drilling campaign. Onshore basins of genuine scale that remain undrilled are increasingly rare. Most of the world's major hydrocarbon-producing regions have been systematically tested…

ThursdayApr 23, 2026 9:00 am

Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) Is ‘One to Watch’

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF)and may include paid advertising. Planet Ventures provides shareholders with exposure to private space and aerospace companies through a publicly traded investment vehicle. The company employs a diversified portfolio strategy spanning infrastructure, software, energy, robotics, and emerging space applications. Its investment approach is positioned to benefit from the continued growth and commercialization of the global space sector. Recent activity includes investments in Relativity Space (via MCXGP), Antaris following its $28 million Series A financing, and General Astronautics, a Y Combinator Winter 2026 company. The company has also deployed capital into…

WednesdayApr 22, 2026 10:30 am

The Private Access Thesis: How Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) (FSE: P6U) Gained Exposure to Relativity Space’s Next Phase

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) (FSE: P6U) and may include paid advertising. Planet Ventures Inc. recently invested USD$125,000 in MCXGP Relativity Fund I, LLC, a special purpose vehicle that participated in the latest financing round of Relativity Space Inc. Relativity Space, led by former Google CEO Eric Schmidt since 2025, is advancing the Terran R fully reusable launch vehicle while also exploring orbital data centers optimized for artificial intelligence workloads. The investment adds to Planet Ventures’ growing space sector portfolio, which previously included exposure to orbital energy infrastructure and cislunar development opportunities. The private space sector…

WednesdayApr 22, 2026 9:00 am

CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Sees 2026 to Be the Company’s Best Year Yet

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising. CMX Gold & Silver Corp., advancing the historic brownfield Clayton Silver Mine in Idaho, expects 2026 to be its most important and transformative year yet. In March, the company acknowledged promising geological indicators that further validated its commitment to advancing operations at its Clayton Silver Project. The mine’s clearly positive geology, together with the fact that it was never fully tapped or even explored, points to the property’s waiting potential. To speed progress, the company has undertaken a non-brokered private placement financing for aggregate…

TuesdayApr 21, 2026 9:00 am

Current Solana and Cryptocurrency Prices Seen as Opportunity to Buy Low Amidst Ongoing Concerns About Debt and Fiat Currencies

The crypto market as a whole goes through many ups and downs, and the current prices provide a unique opportunity for investors to buy low. In addition to investors taking advantages of prices, companies see a chance to manage their own shares, such as Forward Industries, a company building and managing a large-scale Solana treasury. Specifically, Forward Industries recently entered into an agreement to repurchase shares from an institutional investor. Solana and the rest of the crypto market has gone through many ups and downs over the last few years. The current volatility and pressures in the market, encouraged by…

FridayApr 17, 2026 12:10 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease. SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug…

FridayApr 17, 2026 11:30 am

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Gains Relevance as Inflation, Conflict and Central-Bank Demand Reshape Gold

Disseminated on behalf of  Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising. Central bank gold buying has been unfolding against an international scenario that continues to favor safe-haven assets. Lahontan is working to build value through continued drilling, metallurgical work and project advancement. The company is showing a steady stream of updates this year, including drilling and key financing. Gold’s appeal rarely rests on a single catalyst, and the current environment is no exception. Rising geopolitical tension, stubborn inflation risk, elevated sovereign debt and continued official-sector buying are all feeding the case for a renewed gold cycle,…

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

ThursdayApr 16, 2026 11:15 am

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Nears Drill Program Start as Part of Multi-Pronged Gold Revenue Strategy

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising. Canadian near-term precious metal producer ESGold is advancing toward the May start of a drill program expected to further define priority targets on its 20,618-hectare Montauban Gold-Silver Project in Quebec The company is simultaneously working to construct a fully permitted mill on site and expand the scope of its exploration ESGold is employing a low CapEx strategy that includes funding from a private placement initiative and an agreement with Ocean Partners UK Ltd. that provides a credit facility and a dedicated buyer of gold and silver…

ThursdayApr 16, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting. In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma. Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides both an encouraging…

Site Search

Company Search

Category: News